BL-M08D1

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

BL-M08D1 is one of 77 small molecule programs targeting Nasopharyngeal Carcinoma (NPC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal Carcinoma (NPC)Not yet recruiting

Digestive Tract TumorsNot yet recruiting

Gastrointestinal TumorsNot yet recruiting

Head and Neck Squamous Cell CarcinomasNot yet recruiting

Gynecological TumorsNot yet recruiting

Locally Advanced or Metastatic Solid TumorsRecruiting

Relapsed or RefractoryRecruiting

Nasopharyngeal Carcinoma (NPC)Preclinical

Not yet recruiting

Digestive Tract TumorsPreclinical

Not yet recruiting

Gastrointestinal TumorsPreclinical

Not yet recruiting

Head and Neck Squamous Cell CarcinomasPhase 2

Not yet recruiting

Gynecological TumorsPreclinical

Not yet recruiting

Locally Advanced or Metastatic Solid TumorsPhase 1

Recruiting

Relapsed or RefractoryPhase 1

Recruiting

Competition

Competitive Landscape

59 competitors in Relapsed or Refractory

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 2

Decadron

AAspen Global Incorporated

Phase 3

4 3

Copiktra

SSecuraBio

Phase 3

2 4

Venclexta

AbbVie

Phase 2

7 5

Fludara

Sanofi

Phase 2

7 6

Cytosar

Teva

Phase 2

6 7

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

5 8

Oncovin

Eli Lilly

Phase 2

3 9

Fludara

Sanofi

Phase 2

2 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT06718621

Q4 2027

Phase 1Recruiting

Relapsed or Refractory

NCT06718634

Q4 2028

PreclinicalNot yet recruiting

Nasopharyngeal Carcinoma (NPC)

NCT07818486

PreclinicalNot yet recruiting

Diffuse Large B-Cell Lymphoma

NCT07818499

PreclinicalNot yet recruiting

Gynecological Tumors

NCT07793825

Phase 2Not yet recruiting

Head and Neck Squamous Cell Carcinomas

NCT07788950

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06718621·22 enrolled

Relapsed or Refractory1 trial

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06718634·22 enrolled

Nasopharyngeal Carcinoma (NPC)1 trial

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07818486·30 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of BL-M08D1 for Injection in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07818499·204 enrolled

Gynecological Tumors1 trial

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07793825·90 enrolled

2 more indications

Head and Neck Squamous Cell Carcinomas1 trial

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT07788950·30 enrolled

Gastrointestinal Tumors1 trial

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07780318·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BL-M08D1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL-M08D1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL-M08D1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

BL-M08D1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

Relapsed or Refractory1 trial

Nasopharyngeal Carcinoma (NPC)1 trial

Diffuse Large B-Cell Lymphoma1 trial

Gynecological Tumors1 trial

Head and Neck Squamous Cell Carcinomas1 trial

Gastrointestinal Tumors1 trial

References

Drug Info

Quick Facts

Related News